Graft-versus-host Disease (GVHD) Clinical Trial
Official title:
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
| NCT number | NCT05722912 |
| Other study ID # | I 18424-22-02 |
| Secondary ID | |
| Status | Approved for marketing |
| Phase | |
| First received | |
| Last updated |
| Verified date | January 2023 |
| Source | Incyte Corporation |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Expanded Access |
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
| Status | Approved for marketing |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Incyte Corporation |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03112603 -
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
|
Phase 3 | |
| Completed |
NCT03139604 -
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
|
Phase 3 | |
| Completed |
NCT02953678 -
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
|
Phase 2 | |
| Completed |
NCT02614612 -
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
|
Phase 1 | |
| Approved for marketing |
NCT03147742 -
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
|